Organometallic complexes of
fac-tricarbonylrhenium have been shown to exhibit anticancer properties. Anthrapyrazole anticancer agents act as DNA intercalators and topoisomerase IIα inhibitors, leading to double-strand breaks (DBS) and cell cycle arrest. This work involves the synthesis and biological evaluation of novel
fac-tricarbonyl-rhenium complexes with anthrapyrazole derivatives. The anthrapyrazole moiety was synthesized from 1,8-dihydroxyanthraquinone, and three ligands
L1,
L2 and
L3 were prepared. Ligand
L1 coordinates via the phenolic O and pyrazole N as bidentate chelator forming the
fac-[Re(CO)
3(
κ2-N,O)(MeOH)]-type complex,
ReL1. Ligand
L2 contains a pendant picolylamine N,N′-chelating system, forming the bidentate
fac-[Re(CO)
3(
κ2-N,N′)Br]-type complex,
ReL2. Ligand
L3 contains a pendant picolylaminomonoacetic acid chelating system, forming a tridentate
fac-[Re(CO)
3(
κ3-N,N′,O)]-type complex,
ReL3. Complex
ReL4 contains a picolylamine chelator, forming a complex with structure
fac-[Re(CO)
3(
κ2-N,N′)Br], which was synthesized as a model for
ReL2, and its coordination mode was resolved by X-ray crystallography. The complexes were characterized spectroscopically, and their biological properties were evaluated in vitro, in terms of DNA binding as well as for the cytotoxicity against CT-26 tumor cell line. Tumor cell cytotoxicity was high for ligand
L2 and complex
ReL2, exhibiting IC
50 values of 0.36 and 0.64 μΜ, respectively. The most promising complex
ReL2 was evaluated further by the preparation of its congener γ-emitting technetium-99m radio-complex,
99mTcL2. The in vitro uptake in CT26 tumor cells and the in vivo uptake in CT26 tumor-bearing mice of
99mTcL2 was determined, and its pharmacokinetic profile was established. These data indicate that the
99mTc complex has suitable properties to enter tumor cells in vitro and in vivo, and therefore
ReL2 is promising for further evaluation.
Full article